A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

VTYX Insider Trading (Ventyx Biosciences)

Insider Ownership Percentage: 49.10%
Insider Buying (Last 12 Months): $5,000,000.00
Insider Selling (Last 12 Months): $0.00

Ventyx Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Ventyx Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ventyx Biosciences Share Price & Price History

Current Price: $18.26
Price Change: Price Increase of +1.22 (7.16%)
As of 08/12/2022 01:00 AM ET

This chart shows the closing price history over time for VTYX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Is Apple Pointing to a Massive Recession in the U.S.?
Apple (AAPL) is making moves behind the scenes to prepare for a downturn…Bloomberg recently reported that the tech giant plans to freeze hiring in some divisions- while remaining cautious on spending through next year. And the thing is, Apple isn’t alone…Bottom-line: Apple might be pointing to a massive recession in the U.S. If you have any serious assets in the market, there is one critical step you must take now.
Click for THE one critical step you must take now.

Ventyx Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2021Global Strategic Fund I VenbioMajor ShareholderBuy312,500$16.00$5,000,000.00View SEC Filing Icon  
See Full Table
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

SEC Filings (Institutional Ownership Changes) for Ventyx Biosciences (NASDAQ:VTYX)

62.30% of Ventyx Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VTYX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Ventyx Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/13/2022American International Group Inc.10,490$0.13M0.0%+102.3%0.021%Search for SEC Filing on Google Icon
8/12/2022Northern Trust Corp166,643$2.04M0.0%+93.2%0.328%Search for SEC Filing on Google Icon
8/12/2022Virtus ETF Advisers LLC7,970$97K0.0%N/A0.016%Search for SEC Filing on Google Icon
8/12/2022FMR LLC1,575,942$19.27M0.0%+92.9%3.099%Search for SEC Filing on Google Icon
8/12/2022Rhumbline Advisers25,437$0.31M0.0%N/A0.050%Search for SEC Filing on Google Icon
8/11/2022UBS Group AG2,052$25K0.0%-28.5%0.004%Search for SEC Filing on Google Icon
8/11/2022JPMorgan Chase & Co.11,984$0.15M0.0%+57.8%0.024%Search for SEC Filing on Google Icon
8/3/2022Janney Montgomery Scott LLC18,934$0.23M0.0%N/A0.037%Search for SEC Filing on Google Icon
6/7/2022Bank of America Corp DE30,680$0.42M0.0%-34.6%0.060%Search for SEC Filing on Google Icon
5/17/2022Great Point Partners LLC336,334$4.56M1.1%N/A0.661%Search for SEC Filing on Google Icon
5/16/2022California State Teachers Retirement System4,428$60K0.0%-22.7%0.009%Search for SEC Filing on Google Icon
5/16/2022Matrix Capital Management Company LP335,000$4.55M0.1%N/A0.658%Search for SEC Filing on Google Icon
5/16/2022Wellington Management Group LLP1,502,971$20.32M0.0%-17.8%2.952%Search for SEC Filing on Google Icon
5/16/2022State Street Corp171,195$2.32M0.0%+65.2%0.336%Search for SEC Filing on Google Icon
5/16/2022UBS Group AG2,868$39K0.0%-24.5%0.006%Search for SEC Filing on Google Icon
5/13/2022Northern Trust Corp86,252$1.17M0.0%-7.6%0.169%Search for SEC Filing on Google Icon
5/13/2022Charles Schwab Investment Management Inc.73,803$1M0.0%+3.5%0.145%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.491,336$6.67M0.0%-0.7%0.965%Search for SEC Filing on Google Icon
5/11/2022Bank of New York Mellon Corp24,242$0.33M0.0%+38.1%0.048%Search for SEC Filing on Google Icon
5/11/2022JPMorgan Chase & Co.7,593$0.10M0.0%-88.0%0.015%Search for SEC Filing on Google Icon
5/5/2022New York State Common Retirement Fund5,375$73K0.0%N/A0.011%Search for SEC Filing on Google Icon
2/19/2022Woodline Partners LP120,000$2.38M0.0%N/A0.239%Search for SEC Filing on Google Icon
2/14/2022Citadel Advisors LLC3,891,028$74.74M0.0%N/A7.736%Search for SEC Filing on Google Icon
2/14/2022venBio Partners LLC5,011,536$99.53M17.9%N/A9.964%Search for SEC Filing on Google Icon
2/14/2022Third Point LLC4,312,834$83.08M0.6%N/A8.575%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp93,365$1.85M0.0%N/A0.186%Search for SEC Filing on Google Icon
2/7/2022American Century Companies Inc.392,750$7.80M0.0%N/A0.781%Search for SEC Filing on Google Icon
1/26/2022Tokio Marine Asset Management Co. Ltd.12,400$0.25M0.0%N/A0.025%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Ventyx Biosciences logo
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Read More on Ventyx Biosciences

Today's Range

Now: $18.26
Low: $16.91
High: $18.84

50 Day Range

MA: $14.62
Low: $11.95
High: $18.26

52 Week Range

Now: $18.26
Low: $9.50
High: $26.00

Volume

356,148 shs

Average Volume

162,287 shs

Market Capitalization

$928.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Ventyx Biosciences?

Ventyx Biosciences' top insider investors include:
  1. Global Strategic Fund I Venbio (Major Shareholder)
Learn More about top insider investors at Ventyx Biosciences.

Who are the major institutional investors of Ventyx Biosciences?

Ventyx Biosciences' top institutional investors include:
  1. FMR LLC — 3.10%
  2. Northern Trust Corp — 0.33%
  3. Rhumbline Advisers — 0.05%
  4. Janney Montgomery Scott LLC — 0.04%
  5. JPMorgan Chase & Co. — 0.02%
  6. American International Group Inc. — 0.02%
Learn More about top institutional investors of Ventyx Biosciences stock.

Which institutional investors are selling Ventyx Biosciences stock?

Within the last quarter, VTYX stock was sold by these institutional investors:
  1. UBS Group AG

Which institutional investors are buying Ventyx Biosciences stock?

During the previous quarter, VTYX stock was acquired by institutional investors including:
  1. FMR LLC
  2. Northern Trust Corp
  3. Rhumbline Advisers
  4. Janney Montgomery Scott LLC
  5. Virtus ETF Advisers LLC
  6. American International Group Inc.
  7. JPMorgan Chase & Co.
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.